Therapeutical Class：4th generation cephalosporins, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(-) coverage similar to 3rd generation cephalosporins with better G(+) coverage.

Administraton：IV or IM.

Adults: 1-2 g q8-12h IV, 0.5-1 g q12h IM.

Brain abscess, febrile neutropenia:2 g q8h;

Intra-abdominal infection, skin infection, severe UTI: 2 g q12h;

Mild to moderate UTI 0.5-1 g q12h;

Pneumonia 1-2 g q8-12h.

Renal impairment: (1) Ccr >60 ml/min, 2 g q8h:

Ccr 30-60 ml/min, 2g q12h;

Ccr 10-29 ml/min, 2 g qd;

Ccr <10 ml/min, 1 g qd.

(2) Ccr >60 ml/min, 2 g q12h:

Ccr 30-60 ml/min, 2g qd;

Ccr 10-29 ml/min, 1 g qd;

Ccr <10 ml/min, 500 mg qd.

(3) Ccr >60 ml/min, 1g q12h:

Ccr 30-60 ml/min, 1g qd;

Ccr 10-29 ml/min, 500 mg qd;

Ccr <10 ml/min, 250 mg qd.

Children: 50 mg/kg q12h, increase dosing frequency to q8h in febrile neutropenia.

Adverse Effect：Diarrhea (1-10%), seizure, headache (1-10%), hypersensitivity, abdominal pain, rash (1-10%), urticaria, pruritus, nausea, vomiting, fever, phlebitis, pseudomembranous colitis, anemia, jaundice, elevation of LFT and BUN/Cr, pain at injection site (1-10%).

Pregnancy Risk：BSupply：Maxipime XE “Maxipime”  Inj 500mg（邁菌平注射劑 必治妥）＜02380＞